The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients

The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients

The prescribing of biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (iJAK) during the COVID-19 pandemic requires a balanced approach and tight monitoring of the patients.The aim of the study was to study the effect of bDMARDs and iJAK inhibitors on the condition...

Full description

Saved in:
Bibliographic Details
Main Authors: A. E. Karateev, E. Yu. Polishchuk, A. S. Potapova, E. V. Matyanova, A. S. Semashko, А. O. Bobkova, E. S. Filatova, V. N. Amirjanova, S. I. Glukhova, E. G. Zotkin, A. M. Lila
Format: Article
Language:Russian
Published: IMA PRESS LLC 2022-05-01
Series:Научно-практическая ревматология
Subjects:
rheumatoid arthritis
biological disease-modifying antirheumatic drugs
jak inhibitors
covid-19
Online Access:https://rsp.mediar-press.net/rsp/article/view/3146
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://rsp.mediar-press.net/rsp/article/view/3146

Similar Items